NASDAQ · BIAFW
Healthcare · Medical - Diagnostics & Research
$0.24
Down-$0.02 (-9.20%)
Updated Nov 6, 2026, 12:21 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BIAFW
1M range · 12 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
BIAFW closed at $0.24 after 12 trading sessions, down 40.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $0.2448 | $0.2448 | $0.2448 | $0.2448 | 292 |
| Oct 29, 2026 | $0.218 | $0.2449 | $0.218 | $0.2448 | 702 |
| Oct 28, 2026 | $0.2375 | $0.2375 | $0.2375 | $0.2375 | 985 |
| Oct 27, 2026 | $0.22 | $0.23 | $0.22 | $0.23 | 1.22K |
| Oct 26, 2026 | $0.1952 | $0.22 | $0.1952 | $0.22 | 1.3K |
| Oct 23, 2026 | $0.319 | $0.319 | $0.1504 | $0.175 | 5.45K |
| Oct 22, 2026 | $0.4191 | $0.4191 | $0.4191 | $0.4191 | 201 |
| Oct 16, 2026 | $0.45 | $0.56 | $0.315 | $0.315 | 1.35K |
| Oct 14, 2026 | $0.46 | $0.46 | $0.301 | $0.3011 | 546 |
| Oct 13, 2026 | $0.538 | $0.5599 | $0.2734 | $0.30 | 3.27K |
| Oct 9, 2026 | $0.5671 | $0.5671 | $0.5671 | $0.5671 | 270 |
| Oct 8, 2026 | $0.60 | $0.6001 | $0.372 | $0.409 | 3.86K |
The latest Smart Investors Daily articles mentioning BIAFW.
Company
Market Activity
Research & News
BIAFW research
Company profile and research snapshot.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 29, 2026
SAN ANTONIO, October 29, 2026--bioAffinity Technologies will share benefits of CyPath Lung with North Carolina lung cancer patient advocacy and healthcare community at Nov. 5 event.
Yahoo · Oct 27, 2026
bioAffinity Technologies CEO Maria Zennes joined Steve Darling from Proactive to discuss the company's noninvasive lung cancer detection technology, reported 200% year-over-year growth in the second quarter, insurance reimbursement and plans to expand its diagnostic platform into chronic obstructive pulmonary disease (COPD) and asthma. Zannes explained that bioAffinity Technologies has developed a diagnostic platform designed to analyse the lung microenvironment and identify signs of disease. Its initial commercial application focuses on lung cancer through a noninvasive test that uses sputum samples collected by patients at home. The samples are analysed using flow cytometry and an artificial intelligence-based algorithm to help determine whether lung cancer is present. The test is prescribed by physicians for patients who may have suspicious lung nodules. According to Zannes, the technology can provide additional information to help physicians assess patients and make decisions about further diagnostic procedures or continued monitoring. On the commercial side, Zannes reported 200% year-over-year growth in the second quarter and said the company was also experiencing year-over-year growth in the third quarter. She highlighted Medicare reimbursement and coverage by most private insurers as important factors supporting the adoption of its diagnostic technology. The company is also exploring opportunities to expand the platform beyond lung cancer. Its development plans include applications in COPD and asthma, where the technology could support precision medicine by helping physicians better characterize lung inflammation and identify patients who may benefit from specific treatments. She also discussed collaborations with AB Medical, which has distribution connections in the Veterans Administration market, and Pictor, a technology partner supporting the development of additional diagnostic capabilities. The Pictor collaboration is expected to contribute molecular and proteomic analysis alongside bioAffinity's existing flow cytometry platform. #proactiveinvestors #bioaffinitytechnologies #nasdaq #biafw #MariaZannes #CHEST2026 #LungHealth #Asthma #COPD #PrecisionMedicine #Biomarkers #ArtificialIntelligence #Diagnostics #LungInflammation #CyPathLung #Biotechnology
Yahoo · Oct 15, 2026
SAN ANTONIO, Texas, October 15, 2026--bioAffinity Technologies sponsors Learning Theater at CHEST 2026 on clinical use of CyPath Lung for detection of lung cancer.
Yahoo · Oct 13, 2026
SAN ANTONIO, October 13, 2026--bioAffinity Technologies to present positive data on new test under development to measure lung inflammation in asthma and COPD at CHEST 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BIAFW.
No results
No recent SID articles mention BIAFW.
